Chemotherapy Combined With Immunotherapy in HER 2 Insertion or Amplification Advanced NSCLC

NCT04324125 · tracked via the Priya Life Science China tracker

Sponsor

Hunan Province Tumor Hospital

Phase

Observational

Started

2020-03-24

Last updated

2024-09-19

Condition(s) studied

Non Small Cell Lung Cancer

Study summary

This study aims to explore the efficacy and safety of chemotherapy or chemotherapy plus PD-1 antibody in HER 2 insertion or amplification.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * ≥18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology * HER 2 Insertion or Amplification * First Diagnosis and Treatment * Treatment Plan is Chemotherapy or Chemotherapy plus PD-1 antibody Exclusion Criteria: * Patients received antitumor treatment before * Patients with contraindication of chemotherapy * Pregnant or breast feeding women

Primary outcome measure(s)

PFS — may 2020- may 2021 (1 year)
Progression free survival

Trial sites (1)

Facility	City	Region	Status
Yongchang Zhang	Changsha	Hunan	Recruiting

More Hunan Province Tumor Hospital trials in China

Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors Recruiting

A Study With Central Nervous System Metastatic EGFR Mutation Positive Non-small Cell Lung Cancer Recruiting

Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK Recruiting

A Real-World Study of Treatment Patterns and Effectiveness in MET Mutation-Positive Advanced Lung Cancer Recruiting

High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases Recruiting

Other trials for the same condition

Dabrafenib and/or Trametinib Rollover Study Recruiting

Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer Recruiting

A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer Recruiting

Cadonilimab Combined With Stereotactic Radiotherapy as Second-line Treatment for Brain Metastases Recruiting

First-in-Human Expanded Cohort Study of Intrapleural Administration of TolueneSulfonamide in Patients With Malignant Pleural Effusion Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04324125 on ClinicalTrials.gov ↗ ← All trials in China